The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
France deserves better than chaos
Yesterday, our country saw citizens take to the streets with legitimate anger and deep concerns, alongside young people profoundly saddened and frightened by this unstable world. But we also witnessed violence, looting and attacks on institutions. In Lyon, our city,...
BIG2026
BIG2026 - the BANG: Auvergne-Rhone-Alpes has talent, audacity and heart! At BIG last Thursday, La French Fab, Les Conseillers du Commerce extérieur de la France, la Société d'Encouragement pour l'Industrie Nationale and our entrepreneurs showcased a region that does...